Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2007 1
2008 5
2009 4
2010 2
2011 4
2012 2
2013 8
2014 6
2015 10
2016 7
2017 7
2018 7
2019 8
2020 4
2021 11
2022 12
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy.
Diez P, Hanna GG, Aitken KL, van As N, Carver A, Colaco RJ, Conibear J, Dunne EM, Eaton DJ, Franks KN, Good JS, Harrow S, Hatfield P, Hawkins MA, Jain S, McDonald F, Patel R, Rackley T, Sanghera P, Tree A, Murray L. Diez P, et al. Among authors: van as n. Clin Oncol (R Coll Radiol). 2022 May;34(5):288-300. doi: 10.1016/j.clon.2022.02.010. Epub 2022 Mar 7. Clin Oncol (R Coll Radiol). 2022. PMID: 35272913
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.
Hanna GG, Murray L, Patel R, Jain S, Aitken KL, Franks KN, van As N, Tree A, Hatfield P, Harrow S, McDonald F, Ahmed M, Saran FH, Webster GJ, Khoo V, Landau D, Eaton DJ, Hawkins MA. Hanna GG, et al. Among authors: van as n. Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14. doi: 10.1016/j.clon.2017.09.007. Epub 2017 Oct 13. Clin Oncol (R Coll Radiol). 2018. PMID: 29033164 Free article.
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Tree AC, et al. Among authors: van as n. Lancet Oncol. 2022 Oct;23(10):1308-1320. doi: 10.1016/S1470-2045(22)00517-4. Epub 2022 Sep 13. Lancet Oncol. 2022. PMID: 36113498 Free article. Clinical Trial.
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus.
Jereczek-Fossa BA, Marvaso G, Zaffaroni M, Gugliandolo SG, Zerini D, Corso F, Gandini S, Alongi F, Bossi A, Cornford P, De Bari B, Fonteyne V, Hoskin P, Pieters BR, Tree AC, Arcangeli S, Fuller DB, Franzese C, Hannoun-Levi JM, Janoray G, Kerkmeijer L, Kwok Y, Livi L, Loi M, Miralbell R, Pasquier D, Pinkawa M, Scher N, Scorsetti M, Shelan M, Toledano A, van As N, Vavassori A, Zilli T, Pepa M, Ost P; on the behalf of the European Society for Radiotherapy, Oncology Advisory Committee on Radiation Oncology Practice (ESTRO ACROP). Jereczek-Fossa BA, et al. Among authors: van as n. Cancer Treat Rev. 2021 Jul;98:102206. doi: 10.1016/j.ctrv.2021.102206. Epub 2021 Apr 20. Cancer Treat Rev. 2021. PMID: 33965893 Review.
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators. Brand DH, et al. Among authors: van as n. Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17. Lancet Oncol. 2019. PMID: 31540791 Free PMC article. Clinical Trial.
Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest London.
Bailey C, Sanderson T, Townsley H, Goldman J, Black JRM, Young G, Goldstone R, Fowler AS, Ward S, Jackson DJ, Cubitt L, Dearing V, O'Neil O, Crawford M, Snell D, Finadis M, Edwards A, Perez-Lloret J, Gahir J, Carr EJ, Riddell A, Aitken J, Ambrose K, Sawyer C, O'Reilly N, Caidan S, Wu MY, Walker PA, Hindmarsh S, Howell M, Jordan A, Fleming J, Houlihan C, Nastouli E, Moores R, Hsu D, Papineni P, Corrah T, Gilson R, MacRae J, Hubank M, Van As N, Turajlic S, Beale R, Levi M; Crick COVID-19 Consortium; Barrell S, Williams B, Gamblin S, Nicod J, Gandhi S, Bauer DLV, Wall EC, Swanton C. Bailey C, et al. Among authors: van as n. Lancet. 2023 Jul 1;402(10395):21-24. doi: 10.1016/S0140-6736(23)00917-0. Epub 2023 Jun 19. Lancet. 2023. PMID: 37348521 Free PMC article. No abstract available.
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.
Wu MY, Shepherd STC, Fendler A, Carr EJ, Au L, Harvey R, Dowgier G, Hobbs A, Herman LS, Ragno M, Adams L, Schmitt AM, Tippu Z, Shum B, Farag S, Rogiers A, O'Reilly N, Bawumia P, Smith C, Carlyle E, Edmonds K, Del Rosario L, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Barber T, Hepworth S, Emslie-Henry A, Caulfield-Lynch N, Byrne F, Deng D, Williams B, Brown M, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Popat S, Yousaf N, Jhanji S, Tatham K, Cunningham D, Van As N, Young K, Furness AJS, Pickering L, Beale R, Swanton C, Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Howell M, Walker S, Nicholson E, Larkin J, Wall EC, Turajlic S; CAPTURE consortium. Wu MY, et al. Among authors: van as n. Cancer Cell. 2023 May 8;41(5):821-823. doi: 10.1016/j.ccell.2023.04.005. Epub 2023 Apr 13. Cancer Cell. 2023. PMID: 37116490 Free PMC article.
In Reply to Onal et al.
Nicholls L, Chapman E, Khoo V, Suh YE, van As N. Nicholls L, et al. Among authors: van as n. Clin Oncol (R Coll Radiol). 2022 Apr;34(4):e173. doi: 10.1016/j.clon.2022.01.009. Epub 2022 Jan 31. Clin Oncol (R Coll Radiol). 2022. PMID: 35093250 No abstract available.
Stereotactic body radiotherapy for prostate cancer.
Henderson DR, Tree AC, van As NJ. Henderson DR, et al. Among authors: van as nj. Clin Oncol (R Coll Radiol). 2015 May;27(5):270-9. doi: 10.1016/j.clon.2015.01.011. Epub 2015 Feb 21. Clin Oncol (R Coll Radiol). 2015. PMID: 25707911 Review.
93 results